We’re developing targeted therapies to lower LDL cholesterol for patients not adequately treated with current lipid-modifying therapies.

Learn More


Esperion is a late-stage pharmaceutical company focused on developing and commercializing non-statin, complementary, once-daily, oral, LDL-C lowering therapies for the treatment of patients with elevated LDL-C.

learn more


ACC Scientific Session Reflections: A Conversation Among Members of The Lipid Management Team

Last week The Lipid Management team attended the American College of Cardiology (ACC) 66th Annual Scientific Session in Washington D.C…. more

Posted by mlowe@esperion.com

Validating Our Approach: Dr. Ference to Present Results from Mendelian Randomization Studies of ACL Inhibition at the Upcoming ACC Scientific Session

As a team of lipid management experts, we often “geek out” on the science behind LDL-cholesterol lowering therapies. That’s why… more

Posted by mlowe@esperion.com

Bringing My Life’s Work to Esperion

As February comes to a close, we reflect on the importance of recognizing American Heart Month, a time dedicated to… more

Posted by mlowe@esperion.com